EUVIMEDEUVIMED entdecken
Crossref

Formulation and evaluation of Liquisolid compact of Nilvadipine for Enhanced Oral Bioavailability

Raj Kumar, Darakhshan G. Bari, Saurabh Sharma, Rizwan Ahmad, Vishal Kumar

International Journal of Drug Delivery Technology · 30.04.2026 · 16 (41s)

DOI: 10.25258/ijddt.16.41s.34 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 30.04.2026. Verfasst von Raj Kumar und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The present study aimed to formulate and evaluate liquisolid compacts of Nilvadipine to enhance its dissolutionrate and oral bioavailability, overcoming limitations associated with its poor aqueous solubility. PEG 400 as a non-volatile solvent, Avicel PH102 as a carrier, and Aerosil 200 as a coating material were used to create liquisolidcompacts. Thirteen formulations (F1–F13) were developed by varying excipient ratios. Pre-compression parameterssuch as angle of repose, bulk density, tapped density, Carr's index, and Hausner ratio were evaluated. Post-compression studies included weight variation, hardness, thickness, friability, wetting time, and drug content. Invitro dissolution studies were carried out using USP type II apparatus in phosphate buffer (pH 6.8). The optimizedformulation was further subjected to kinetic modeling and stability studies as per ICH guidelines. All formulationsshowed acceptable flow properties with Carr's index (9–18%) and Hausner ratio (1.10–1.23). Post-compressionparameters were within pharmacopeial limits, indicating good mechanical strength and uniformity. Wetting timeranged from 48.3 to 55 seconds, and drug content was found between 80.29% and 93%. Among all batches,formulation F1 exhibited maximum drug release (95.47% at 720 min), indicating superior dissolution performance.Kinetic analysis revealed that drug release followed the Higuchi model (R² = 0.9911), suggesting diffusion-controlled release. Stability studies showed no significant changes in friability, drug content, or drug release over 3months. Liquisolid compact technique significantly enhanced the dissolution rate of Nilvadipine. Formulation F1was identified as the optimized batch, exhibiting improved drug release, acceptable physicochemical properties,and good stability. This approach can be considered a promising strategy for improving the oral bioavailability of poorly soluble drugs.

Zitieren

APA

Kumar, R., Bari, D. G., Sharma, S., Ahmad, R., & Kumar, V. (2026). Formulation and evaluation of Liquisolid compact of Nilvadipine for Enhanced Oral Bioavailability. International Journal of Drug Delivery Technology, 16(41s). https://doi.org/10.25258/ijddt.16.41s.34

Vancouver

Kumar R, Bari DG, Sharma S, Ahmad R, Kumar V. Formulation and evaluation of Liquisolid compact of Nilvadipine for Enhanced Oral Bioavailability. International Journal of Drug Delivery Technology. 2026;16(41s). doi:10.25258/ijddt.16.41s.34

BibTeX
@article{Kumar2026,
  author = {Kumar, Raj and Bari, Darakhshan G. and Sharma, Saurabh and Ahmad, Rizwan and Kumar, Vishal},
  title = {Formulation and evaluation of Liquisolid compact of Nilvadipine for Enhanced Oral Bioavailability},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {41s},
  doi = {10.25258/ijddt.16.41s.34}
}
Kostenlos starten →